Personalized medicine in Brazil: a new paradigm, old problems

Autores

  • Claudia Pavani University of São Paulo, São Paulo
  • Guilherme Ary Plonski University of São Paulo, São Paulo

DOI:

https://doi.org/10.1108/INMR-04-2019-0048

Palavras-chave:

Public health, Innovation, Personalized medicine

Resumo

Purpose – Personalized medicine (PM) encompasses a set of procedures, technologies and medications;
the term became more prominent from the 2000s onwards and stems from the mapping of the human
genome. The purposes of this study were to analyse the development stage of the process of
technological innovation for PM and the obstacles that prevent PM from being adopted in the public
health system in Brazil.
Design/methodology/approach – As a research method, this paper opts for a case study carried out at
the Hospital das Clínicas, which belongs to São Paulo Medical School. In total, 22 in-depth interviews were
carried out at the hospital to identify current practices in PM, future prospects and barriers imposed to the
adoption of PM technologies in public health.
Findings – Personalized or precision medicine is already a reality for a small portion of the Brazilian
population and is gradually gaining ground in public health care. One finding is that such changes are
occurring in a disjointed manner in an incomplete and under development health innovation system. The
analysis pointed out that the obstacles identified in Brazil are the same as those faced by high-income
countries such as regulation, lack of clinical studies and need to adapt clinical studies to PM. They appear in
all stages of the innovation cycle, from research to widespread use.
Research limitations/implications – The research method was a case study, so the findings cannot be
extrapolated to other contexts. A limited number of professionals were interviewed, their opinions may not
reflect those of their organizations.
Originality/value – There are several studies that discuss how health-care systems in high-income
countries could incorporate these new technologies, but only a few focuses on low or middle-income countries
such as Brazi

Downloads

Não há dados estatísticos.

Referências

Agência Brasil. (2020). Projeto liderado por brasileira mapeara genoma de 15 mil pessoas.

Retrieved from https://agenciabrasil.ebc.com.br/saude/noticia/2019-12/projeto-liderado-porbrasileira-mapeara-genoma-de-15-mil-pessoas

Agência Nacional de Saúde (ANS) (2019a). Agência nacional de saúde suplementar. Retrieved from www.ans.

gov.br/aans/noticias-ans/numeros-do-setor/4926-ans-disponibiliza-numeros-de-fevereiro-do-setor

Agência Nacional de Saúde (ANS) (2019b). Agência nacional de saúde suplementar. Retrieved from

www.ans.gov.br//aans/index.php/750-central-de-atendimento-o-que-o-seu-plano-deve-cobrir

Banta, H. D., & Luce, B. R. (1993). Health care technology and its assessment: An international

perspective (pp. 1–5), New York, NY: Oxford University Press.

Bilkey, G. A., Burns, B. L., Coles, E. P., Mahede, T., Baynam, G., & Nowak, K. J. (2019). Optimizing precision

medicine for public health. Frontiers in Public Health, 7(42), 1–9. doi: https://doi.org/10.3389/

fpubh.2019.00042.

Blank, S. (2013). Why the lean start-up changes everything. Harvard Business Review, 91(5), 63–72.

Boro, P., & Kishore, J. (2016). Precision medicine in public health. Int J Preven Curati Comm Med,

(3&4), 1–3.

De Negri, F., & Uziel, D. (2020). O que é medicina de precisão e como ela pode impactar o setor de saúde? –

Report no. 2557 to the instituto de pesquisa econômica aplicada. Instituto de Pesquisa Econômica

Aplicada [IPEA]. Retrieved from http://repositorio.ipea.gov.br/bitstream/11058/9970/1/td%202557.pdf

Food and Drug Administration (FDA). (2019). Companion diagnostics. Retrieved from https://www.fda.

gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm407297.htm

Food and Drug Administration (FDA). (2020). Real-world evidence. Retrieved from https://www.fda.

gov/science-research/science-and-research-special-topics/real-world-evidence

Eisenhardt, K. M. (1989). Building theories from case study research. Academy of Management Review,

(4), 532–550. doi: https://doi.org/10.5465/amr.1989.4308385.

Greenhalgh, T., Robert, G., Macfarlane, F., Bate, P., & Kyriakidou, O. (2004). Diffusion of innovations in

service organizations: Systematic review and recommendations. The Milbank Quarterly, 82(4),

–629. doi: https://doi.org/10.1111/j.0887-378X.2004.00325.x.

Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. New England Journal of

Medicine, 363(4), 301–304. doi: https://doi.org/10.1056/NEJMp1006304.

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP) (2019).

Relatorio de atividades – Resultados da gestão 2015-2018. Retrieved from http://www.hc.fm.usp.

br/images/pdf/superintendencia/relatorios/Relatorio_Atividades_HC_2015_2018%20v2.pdf

International Network of Agencies for Health Technology Assessment (INAHTA) (2020). Retrieved

from http://www.inahta.org/

Iriart, J. A. B. (2019). Medicina de precisão/medicina personalizada: Analise crítica dos movimentos de

transformação da biomedicina no início do século XXI. Cadernos de Saúde Pública, 35(3),

e00153118 doi: https://doi.org/10.1590/0102-311x00153118.

Jackson, D. J. (2011). What is an innovation ecosystem. National Science Foundation, 1(2), 1–13.

Khoury, M. J., & Galea, S. (2016). Will precision medicine improve population health? JAMA, 316(13),

–1358. doi: https://doi.org/10.1001/jama.2016.12260.

Lippi, G., & Plebani, M. (2015). Personalized medicine: Moving from simple theory to daily practice.

Clinical Chemistry and Laboratory Medicine, 53(7), 959–960.

Ministério da Saúde (MS). (2014a). Diretrizes para atenção integral às pessoas com doenças raras no

sistema único de saúde. Retrieved from https://portalarquivos2.saude.gov.br/images/pdf/2014/

junho/04/DIRETRIZES-DOENCAS-RARAS.pdf

Ministério da Saúde (MS). (2014b). Procedimentos laboratoriais para diagnostico de doenças raras

associadas a anomalias congênitas na tabela SUS (report no. 109). Retrieved from http://conitec.

gov.br/images/Incorporados/DoencasRaras-EixosI-II-III-FINAL.pdf

National Institutes of Health (NIH). (2019). The human genome project. Retrieved from https://www.genome.

gov

Nofziger, C., Papaluca, M., Terzic, A., Waldman, S., & Paulmichl, M. (2014). Policies to aid the adoption of

personalized medicine. Nature Reviews Drug Discovery, 13(3), 159–160. doi: https://doi.org/10.1038/

nrd4257.

Novaes, H. M. D., & Soarez, P. C. (2015). Avaliação de tecnologias em saúde: Técnicas, praticas e

políticas. In Costa, L., Bahia, C. & Gadelha, C. (Eds), Saúde, desenvolvimento e inovação, pp. 327–

Editora Fiocruz.

Olstad, D. L., & McIntyre, L. (2019). Reconceptualising precision public health. BMJ Open, 9(9), 1–9. doi:

https://doi.org/10.1136/bmjopen-2019-030279.

Redekop, W. K., & Mladsi, D. (2013). The faces of personalized medicine: A framework for understanding its

meaning and scope.Value in Health, 16(6), S4–S9. doi: https://doi.org/10.1016/j.jval.2013.06.005.

Schumann, G., Benegal, V., Yu, C., Tao, S., Jernigan, T., Heinz, A., ... Calhoun, V. (2019). Precision

medicine and global mental health. The Lancet Global Health, 7(1), e32 doi: https://doi.org/

1016/S2214-109X(18)30406-6.

Santos, R. D., Mata, P., & Stoll, M. (2015). Hipercolesterolemia familiar, Conectfarma Publicações Científicas.

The White House. (2012). National bioeconomy blueprint. Retrieved from https://obamawhitehouse.

archives.gov/sites/default/files/microsites/ostp/national_bioeconomy_blueprint_april_2012.pdf

Tigre, P. B., & Nascimento, C. V. F. (2015). Teorias da inovação e trajetorias tecnologicas na saúde. in Costa, L.,

Bahia, L. & Gadelha, C. (Eds), Saúde, desenvolvimento e inovação, pp. 17–40. Editora Fiocruz. I

Waldman, S. A., & Terzic, A. (2014). Managing the innovation supply chain to maximize personalized

medicine. Clinical Pharmacology & Therapeutics, 95(2), 113–118. doi: https://doi.org/10.1038/

clpt.2013.228.

Weston, A. D., & Hood, L. (2004). Systems biology, proteomics, and the future of health care: Toward

predictive, preventative, and personalized medicine introduction: Paradigm changes in health

care. Journal of Proteome Research, 3(2), 179–196. doi: https://doi.org/10.1021/pr0499693.

Downloads

Publicado

2021-12-03

Como Citar

Pavani, C. ., & Plonski, G. A. (2021). Personalized medicine in Brazil: a new paradigm, old problems. INMR - Innovation & Management Review, 18(4), 365-381. https://doi.org/10.1108/INMR-04-2019-0048

Edição

Seção

Artigos